Allianz SE bought a new stake in Amrize Ltd (NYSE:AMRZ – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,610 shares of the company’s stock, valued at approximately $80,000.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Credit Industriel ET Commercial acquired a new stake in Amrize in the second quarter valued at about $109,000. Private Capital Advisors Inc. acquired a new stake in shares of Amrize in the 2nd quarter valued at approximately $233,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Amrize in the 2nd quarter valued at approximately $244,000. Virtus Family Office LLC bought a new stake in shares of Amrize during the 2nd quarter valued at approximately $253,000. Finally, Rathbones Group PLC acquired a new position in Amrize during the 2nd quarter worth approximately $257,000.
Insider Buying and Selling
In other news, insider Jaime Hill purchased 4,000 shares of the stock in a transaction on Tuesday, November 4th. The stock was purchased at an average price of $50.69 per share, for a total transaction of $202,760.00. Following the acquisition, the insider owned 18,101 shares in the company, valued at $917,539.69. This trade represents a 28.37% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Roald Brouwer purchased 4,000 shares of the company’s stock in a transaction dated Friday, October 31st. The stock was purchased at an average price of $51.77 per share, for a total transaction of $207,080.00. Following the transaction, the chief technology officer directly owned 9,000 shares in the company, valued at approximately $465,930. This trade represents a 80.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 65,500 shares of company stock valued at $3,433,595 over the last ninety days.
Amrize Stock Down 1.6%
Amrize (NYSE:AMRZ – Get Free Report) last announced its earnings results on Wednesday, October 29th. The company reported $0.98 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.03). The firm’s quarterly revenue was up 6.6% on a year-over-year basis.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the stock. Oddo Bhf assumed coverage on shares of Amrize in a research report on Monday, November 3rd. They issued a “neutral” rating on the stock. Citigroup increased their price target on Amrize from $60.00 to $63.00 and gave the company a “buy” rating in a research note on Monday, November 3rd. Wall Street Zen raised Amrize to a “hold” rating in a report on Saturday, October 25th. JPMorgan Chase & Co. upped their target price on Amrize from $52.00 to $60.00 and gave the stock an “overweight” rating in a report on Tuesday, August 26th. Finally, Barclays initiated coverage on Amrize in a research report on Tuesday, October 7th. They issued an “equal weight” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $58.88.
Read Our Latest Report on Amrize
Amrize Profile
Amrize AG focuses on building materials business in North America. The company was incorporated in 2023 and is based in Zug, Switzerland. Amrize AG operates independently of Holcim AG as of June 23, 2025.
Featured Stories
- Five stocks we like better than Amrize
- Stock Market Sectors: What Are They and How Many Are There?
- Are These 3 Oversold Tech Giants Ready to Rebound?
- What is a Secondary Public Offering? What Investors Need to Know
- If You Wait for the Dip, Micron Technology Could Leave You Behind
- How to Use the MarketBeat Stock Screener
- 3 Stocks Quietly Powering the AI and Tech Revolution
Receive News & Ratings for Amrize Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amrize and related companies with MarketBeat.com's FREE daily email newsletter.
